All In Biotech

NDA 020338 · Galderma Labs Lp

Differin

Adapalene · Topical

NovelDiscontinued

Last checked: Nov 20, 2026Latest source record: Apr 8, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 31, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

112

28 Phase 3, 7 recruiting

FAERS reports

6,328

864 serious, 25 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 31, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • DIFFERIN · ADAPALENE 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, TOPICAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Adapalene" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,537
  • dry skin941
  • skin burning sensation574
  • acne553
  • skin irritation535
  • erythema504
  • condition aggravated442
  • rash405
  • skin exfoliation352
  • therapy cessation227
  • pruritus205
  • hypersensitivity182

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200413
200512
200626
20079
200828
200926
201033
201178
201262
201358
201471
2015118
2016118
201772
201882
2019175
2020128
2021108
2022155
2023195
2024832
2025878
20263,051

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Differin (Adapalene)

2024 spending

$58K

Beneficiaries

77

124 claims

Per beneficiary

$748

$9.03 per unit

View as table
YearSpending
2020$140,908
2021$123,488
2022$111,263
2023$93,764
2024$57,572

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 220 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.